NCT07052032 is a Phase 1 clinical trial of CND261 in Rheumatoid Arthritis, sponsored by Candid Therapeutics.

Who is sponsoring NCT07052032?

NCT07052032 is sponsored by Candid Therapeutics.

What drugs are being tested in NCT07052032?

Interventions in NCT07052032: CND261.

What condition does NCT07052032 study?

NCT07052032 studies Rheumatoid Arthritis.

Is NCT07052032 still recruiting?

NCT07052032 is currently active, enrolled. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT07052032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Active, enrolled Phase 1 Last updated 16 April 2026

What this trial tests

Phase 1 trial testing CND261 in Rheumatoid Arthritis in 47 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 June 2025

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Candid Therapeutics
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	16 June 2025
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	3 locations across Georgia, Ukraine, Moldova

Drugs / interventions tested

CND261 — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Candid Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the safety and efficacy of CND261 in patients with seropositive rheumatoid arthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07052032 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Candid Therapeutics
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07052032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing